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Abstract
Background: Adiponectin and resistin are adipokines which modulate insulin action, energy, glucose and lipid
homeostasis. Meta-analyses showed that hypoadiponectinemia and hyperresistinemia are strongly associated with
increased risk of insulin resistance, type 2 diabetes (T2DM), metabolic syndrome (MS) and cardiovascular disease.
The aim of this study was to propose a novel adiponectin-resistin (AR) index by taking into account both
adiponectin and resistin levels to povide a better indicator of the metabolic homeostasis and metabolic disorders.
In addition, a novel insulin resistance (IRAR) index was proposed by integration of the AR index into an existing
insulin resistance index to provide an improved diagnostic biomarker of insulin sensitivity.
Methods: In this case control study, anthropometric clinical and metabolic parameters including fasting serum
total adiponectin and resistin levels were determined in 809 Malaysian men (208 controls, 174 MS without T2DM,
171 T2DM without MS, 256 T2DM with MS) whose ages ranged between 40-70 years old. Significant differences in
continuous variables among subject groups were confirmed by ANCOVA or MANCOVA test using 1,000 stratified
bootstrap samples with bias corrected and accelerated (BCa) 95% CI. Spearman’s rho rank correlation test was used
to test the correlation between two variables.
Results: The AR index was formulated as 1+log10(R0)-log10(A0). The AR index was more strongly associated with
increased risk of T2DM and MS than hypoadiponectinemia and hyperresistinemia alone. The AR index was more
strongly correlated with the insulin resistance indexes and key metabolic endpoints of T2DM and MS than
adiponectin and resistin levels alone. The AR index was also correlated with a higher number of MS components
than adiponectin and resistin levels alone. The IRAR index was formulated as log10(I0G0)+log10(I0G0)log10(R0/A0). The
normal reference range of the IRAR index for insulin sensitive individuals was between 3.265 and 3.538. The
minimum cut-off values of the IRAR index for insulin resistance assessment were between 3.538 and 3.955.
Conclusions: The novel AR and IRAR indexes are cost-effective, precise, reproducible and reliable integrated
diagnostic biomarkers of insulin sensitivity for screening subjects with increased risk of future development of
T2DM and MS.
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The world prevalence of diabetes among adults will be
6.4%, affecting 285 million adults, in year 2010, and will
increase to 7.7%, and 439 million adults by year 2030
[1]. Malaysia is listed as the top 10 countries with the
highest prevalence of diabetes in recent global estimate
of the prevalence of diabetes for years 2010 and 2030
[1]. In addition, a recent nationwide survey showed that
Malaysia has a much higher prevalence of metabolic
syndrome (MS) compared with other Asian countries
[2]. Insulin resistance is a prerequisite root factor for
development of type 2 diabetes (T2DM) [3]. It is also
the most unifying parameter to characterize the patho-
physiology of the MS [3]. The MS drives the twin global
epidemics of T2DM and cardiovascular disease [4].
T2DM itself is accompanied by increased risk for cardi-
ovascular disease which is aggravated by the concomi-
tant risk factors of the MS [4]. Adiponectin [5] and
resistin [6] hormones are thought to link T2DM and
MS with cardiovascular risk.
Adiponectin is an adipocyte-secreted polypeptide hor-
mone with molecular weight 30 kDa (244 amino acids)
which modulates a number of metabolic processes, and
regulates insulin sensitivity and energy homeostasis, as
well as glucose and lipid metabolism [7]. The hormone
plays a principal role in the suppression of the metabolic
derangements that may result in insulin resistance,
T2DM, MS, and cardiovascular disease [5,8,9].
Resistin is a macrophage-derived signalling polypep-
tide hormone with molecular weight 12.5 kDa and its
length is 108 amino acids in humans [10]. In contrast
with adiponectin, resistin has low circulating levels [10].
However, the blood circulating levels of resistin have
been shown to be up-regulated in subjects with insulin
resistance, T2DM, MS, and cardiovascular disease [6,11].
The concurrence of hypoadiponectinemia [5,8,9] and
hyperresistinemia [6,10] in subjects with insulin resis-
tance, T2DM and MS risk are well-established. A signif-
icant inverse correlation between adiponectin and
resistin levels has also been reported in the literatures
[12,13]. The overall structure of multimeric assembly or
oligomerization of resistin is similar to that of adiponec-
tin [14]. Taking these studies together, it may be specu-
lated that adiponectin and resistin share a common
regulatory mechanism to mediate the body metabolism
(e.g. energy, glucose and lipid homeostasis). Thus, a
novel adiponectin-resistin (AR) index was proposed by
taking into account both adiponectin and resistin levels
to povide a better indicator of the metabolic homeosta-
sis and metabolic disorders.
Established direct methods to quantify insulin sensitivity,
such as euglycemic hyperinsulinemic clamp technique, are
complex, troublesome, expensive, time-consuming, labor-
ious and impractical in clinical practice. Surrogate indexes
are available, but there are no universal cutoff points to
define insulin resistance. Moreover, the existing surrogates
indexes have low sensitivity and lack robustness for early
diagnosis of insulin resistance in the general population. It
is therefore of great interest to establish a convenient,
cost-effective and reliable insulin sensitivity index. Thus, a
novel insulin resistance (IRAR) index was proposed by inte-
gration of the AR index into an existing insulin resistance
index to provide a more promising biomarker of insulin
sensitivity for early diagnosis of T2DM and MS in the
daily clinical practice and for large-scale clinical investiga-
tion. It also allows early treatment to prevent or to delay
the onset of long-term severe complications including
cardiovascular risk.
Methods
Subjects
All subjects were native to Malaysia and were males to
avoid confounding effect of gender. The ages for all sub-
jects were restricted to 40-70 years old because indivi-
duals with 40-70 years old contribute the majority cases
of T2DM and MS. Subjects comprised three primary
ethnic groups which were Malay, Chinese and Indian.
Ethical clearance (reference number of Ethical Approval
Letter was 612.17) to undertake this study was obtained
from the University Malaya Medical Centre (UMMC)
Ethics Committee. Informed consent was obtained from
each subject, to whom possible consequences of the stu-
dies were explained. Each subject received a detailed
questionnaire about the personal and family disease his-
tory and demographic data.
A case control study was designed. The subjects were
classified into 208 controls, 174 MS without T2DM, 171
T2DM without MS, 256 T2DM with MS for a total 809
subjects. The controls were non-diabetic subjects who
had no personal and family history and had no first
degree relatives such as parent and sibling with T2DM
and MS. The fasting plasma glucose levels for a control
was in the normal range (<5.60 mmol/L) according to
American Diabetes Association (ADA) 2003 diagnostic
criteria [15]. Type 2 diabetes (T2DM) were identified as
diabetic subjects who had fasting plasma glucose levels
of ≥7.0 mmol/L and had been diagnosed by a diabetic
physician with T2DM or had been taking diabetic
medication.
Metabolic syndrome (MS) was defined according to
International Diabetes Federation (IDF) 2005 diagnostic
criteria [4]. According to the International Diabetes
Federation (IDF) 2005 diagnostic criteria, for a person
to be defined as having the MS they must have: central
obesity (≥90 cm for South Asians male population),
plus any two of the following four factors, which were
raised triglycerides (≥1.70 mmol/L), reduced HDL cho-
lesterol (<1.03 mmol/L in males), raised blood pressure
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and raised fasting plasma glucose (≥5.60 mmol/L or
previously diagnosed T2DM).
The controls and subjects with T2DM or MS were
selected from those attending the University Malaya
Medical Centre (UMMC) for routine medical check-up
or treatment. All subjects had not been diagnosed with
other hereditary (e.g. cancer and cardiovascular disease)
and infectious diseases (e.g. hepatitis) (Additional file 1,
Supplementary Methods).
Determination of anthropometric clinical and metabolic
parameters
The metabolic parameters including fasting serum total
adiponectin (Additional file 1, Figure S1A), resistin
(Additional file 1, Figure S1B), insulin, total cholesterol,
LDL cholesterol, HDL cholesterol, triglyceride, plasma
glucose, and whole blood HbA1C levels were tested.
T h ea n t h r o p o m e t r i cp a r a m eters including the blood
pressure, body mass index (BMI), waist circumference,
and waist-to-hip ratio (WHR), were also measured or
calculated. Surrogate indexes of insulin sensitivity
including quantitative insulin sensitivity check index
(QUICKI), homeostasis model assessment of insulin
resistance (HOMA-IR) index, Bennett index, McAuley
(1) index and McAuley (2) index were calculated (Addi-
tional file 1, Table S1).
Statistical analysis
Significant differences in continuous variables among
subject groups were confirmed by univariate analysis of
covariance (ANCOVA) or multivariate analysis of covar-
iance (MANCOVA) with PASW Statistics 18 Program
(SPSS Inc, Chicago, Illinois, USA). General linear model
was used, in which each subject group was included as a
fixed factor. The models included ages as covariate. Type
III sum-of-squares method was used. Then, 1,000 strati-
fied bootstrap samples with bias corrected and acceler-
ated (BCa) 95% confident interval were used for pair wise
comparisons. Stratified bootstrapping method was used
for stratified ethnicity and for multiple testing bias cor-
rections due to deviation of normality. Spearman’sr h o
rank correlation test was used to test the correlation
between two variables. Nonparametric correlation test
was used because most of the variables are not normally
distributed. All p-values were two-tailed, and p-values
below 0.05 were considered statistically significant.
Results
Clinical features of T2DM and MS subjects
The clinical characteristics of the controls, and subjects
with type 2 diabetes (T2DM), and metabolic syndrome
(MS) are shown in Table 1 and Table 2, which reflect
the criteria used to define the subject groups. There was
homogeneity for the covariate in terms of ages and eth-
nicity to match the case-control groups (Table 1). Sub-
jects with T2DM and MS had higher (df = 3; F =
15.096; P = 1.45 × 10
-9) serum insulin levels than the
healthy subjects (Table 2). Serum insulin levels were the
highest in subjects presenting with both T2DM and MS
(Table 2).
Serum adiponectin levels
Hypoadiponectinemia was strongly associated (df = 3;
F = 13.900; P = 7.65 × 10
-9) with increased risk of type
2 diabetes (T2DM) and metabolic syndrome (MS) in
Malaysian men (Figure 1). Serum adiponectin levels
were significantly lower in MS subjects who do not yet
manifest T2DM as compared to the healthy subjects
(Figure 1). Serum adiponectin levels were also lower in
T2DM subjects who do not yet manifest MS as com-
pared to the healthy subjects (Figure 1). Interestingly,
serum adiponectin levels were further down-regulated in
subjects presenting with both T2DM and MS (Figure 1).
These findings were consistent with previous reports on
adiponectin in most epidemiological studies [5,8,16] and
meta-analyses [9].
Serum adiponectin levels were positively correlated
with serum HDL cholesterol levels, QUICKI, Bennett,
McAuley (1) and McAuley (2) indexes, and it was nega-
tively correlated with BMI, waist, WHR, HOMA-IR
index, serum triglyceride, insulin, resistin, plasma glu-
cose and whole blood HbA1C levels (Table 3 and Table
4). The strongest correlation of serum adiponectin levels
was with the insulin resistance indexes, serum HDL
cholesterol, triglyceride and insulin levels (Table 3 and
T a b l e4 ) .T a k i n gt h e s ef i n d i n g st o g e t h e r ,i ts h o w e dt h a t
adiponectin plays an important role in the modulation
of lipid homeostasis (e.g. fatty acids oxidation) and insu-
lin sensitivity. Adiponectin may also involve in the med-
iation of glucose homeostasis.
Serum resistin levels
Hyperresistinemia was strongly associated (df = 3; F =
49.165; P = 3.52 × 10
-29) with increased risk of type 2 dia-
betes (T2DM) and metabolic syndrome (MS) in Malaysian
men (Figure 2). Serum resistin levels were significantly
higher in T2DM subjects who do not yet manifest MS
as compared to the healthy subjects (Figure 2). However,
there was no significant difference in serum resistin levels
between the healthy and MS subjects who do not yet
manifest T2DM (Figure 2). Hyperresistinemia was
more severe in subjects presenting with both T2DM and
M S( F i g u r e2 ) .T h e s ef i n d i n g sw e r ec o n s i s t e n tw i t h
previous reports on resistini nm o s te p i d e m i o l o g i c a l
studies [6,11].
Serum resistin levels were positively correlated with
BMI, waist, WHR, HOMA-IR index, serum insulin,
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Subjects
Variables Control
(n = 208)
group A
MS
without T2DM
(n = 174)
group B
T2DM
without MS
(n = 171)
group C
T2DM
with MS
(n = 256)
group D
F-test; P-value
(A vs. B vs. C vs. D)
Ethnics (Malay/Chinese/Indian) 75/73/60
C*
62/54/58
NS
43/62/66
A*, D**
101/75/80
C**
11.350; 0.0780
Ages (years) 55 (54, 56)
D*
54 (53, 55)
NS
55 (54, 56)
D*
53 (52, 54)
A*, C*
2.174; 0.0897
Diabetic medication (oral/injection) NA NA 157/14 197/59 NA
Duration of diabetes (years) NA NA 9 (8, 10) 8 (7, 9) NA
Family history of diabetes (yes/no) 0/208 45/129 107/64 166/90 NA
Hypertension (yes/no) 0/208 123/51 13/158 219/37 NA
Dyslipidemia (yes/no) 0/208 174/0 0/171 244/12 NA
Smoking (yes/no) 39/169 48/126 55/116 91/165 NA
BMI (kg/m
2) 24.39 (23.92, 24.87) 27.18 (26.69, 27.69) 24.13 (23.60, 24.67) 28.32 (27.84, 28.78) 66.309; 2.56 × 10
-38
B***, D*** A***, C***, D** B***, D*** A***, B**, C***
Waist (cm) 89 (88, 90) 96 (95, 97) 90 (88, 91) 100 (99, 102) 91.987; 3.49 × 10
-51
B***, D*** A***, C***, D*** B***, D*** A***, B***, C***
WHR 0.898 (0.891, 0.904) 0.929 (0.921, 0.938) 0.914 (0.907, 0.922) 0.952 (0.946, 0.957) 50.414; 7.33 × 10
-30
B***, C***, D*** A***, C*, D*** A**, B*, D*** A***, B***, C***
Systolic BP (mmHg) 133 (130, 135) 143 (140, 145) 129 (127, 131) 136 (134, 138) 21.188; 3.23 × 10
-13
B***, C*, D* A***, C***, D*** A*, B***, D*** A*, B***, C***
Diastolic BP (mmHg) 83 (81, 84) 88 (87, 90) 79 (78, 80) 83 (81, 84) 30.591; 9.87 × 10
-19
B***, C*** A***, C***, D*** A***, B***, D*** B***, C***
Data are expressed as mean (95% confident interval). ANCOVA test was used, followed by pairwise comparison using 1,000 stratified bootstrap samples with bias
corrected and accelerated (BCa) 95% CI for multiple testing bias corrections due to deviation of normality. The p-value was also adjusted for covariate ages with
stratified ethnicity. The location of statistically significant differences are displayed as group’s name (A, B, C, or D). Diabetic medication are including oral drugs
(e.g. Metformin and Rosiglitazon) and/or injection of exogenous insulin. Significant levels: P* < 0.05, P** < 0.01, P*** < 0.001. Note: T2DM = type 2 diabetes; MS =
metabolic syndrome; NA = not applicable; NS = not significant.
Table 2 Metabolic parameters for each subject group
Subjects
Variables Control
(n = 208)
group A
MS
without T2DM
(n = 174)
group B
T2DM
without MS
(n = 171)
group C
T2DM
with MS
(n = 256)
group D
F-test; P-value
(A vs. B vs. C vs. D)
Total cholesterol (mmol/L) 5.03 (4.91, 5.14) 5.16 (5.03, 5.29) 4.68 (4.52, 4.85) 4.64 (4.50, 4.78) 12.412; 6.10 × 10
-8
C***, D*** C***, D*** A***, B*** A***, B***
HDL cholesterol (mmol/L) 1.28 (1.25, 1.31) 1.07 (1.03, 1.10) 1.26 (1.22, 1.29) 1.04 (1.01, 1.07) 62.822; 1.70 × 10
-36
B***, D*** A***, C*** B***, D*** A***, C***
LDL cholesterol (mmol/L) 3.14 (3.03, 3.26) 3.09 (2.95, 3.25) 2.88 (2.73, 3.04) 2.69 (2.57, 2.81) 10.656; 7.11 × 10
-7
C**, D*** C*, D*** A**, B* A***, B***
Triglyceride (mmol/L) 1.31 (1.25, 1.37) 2.20 (2.07, 2.34) 1.20 (1.12, 1.27) 2.02 (1.89, 2.16) 68.292; 2.40 × 10
-39
B***, C*, D*** A***, C*** A*, B***, D*** A***, C***
Glucose (mmol/L) 5.13 (5.05, 5.23) 5.51 (5.39, 5.63) 8.04 (7.60, 8.50) 8.26 (7.94, 8.60) 118.021; 2.46 × 10
-63
B***, C***, D*** A***, C***, D*** A***, B*** A***, B***
HbA1C (%) 5.63 (5.57, 5.69) 5.82 (5.76, 5.89) 8.07 (7.78, 8.36) 8.09 (7.90, 8.28) 225.382; 4.32 × 10
-106
B***, C***, D*** A***, C***, D*** A***, B*** A***, B***
Insulin (μU/mL) 10.99 (10.05, 11.97) 19.94 (16.95, 23.42) 14.86 (12.76, 17.04) 24.32 (20.85, 27.95) 15.096; 1.45 × 10
-9
B***, C**, D*** A***, C* A**, B*, D** A***, C**
Data are expressed as mean (95% confident interval). ANCOVA test was used, followed by pairwise comparison using 1,000 stratified bootstrap samples with bias
corrected and accelerated (BCa) 95% CI for multiple testing bias corrections due to deviation of normality. The p-value was also adjusted for covariate ages with
stratified ethnicity. The location of statistically significant differences are displayed as group’s name (A, B, C, or D). Significant levels: P* < 0.05, P** < 0.01, P*** <
0.001. Note: T2DM = type 2 diabetes; MS = metabolic syndrome.
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was negatively correlated with serum HDL cholesterol
and adiponectin levels, QUICKI, Bennett, McAuley (1)
and McAuley (2) indexes (Table 3 and Table 4). Serum
resistin levels had the strongest correlation with the
insulin resistance indexes, plasma glucose and whole
blood HbA1C levels (Table 3 and Table 4). Taking these
f i n d i n g st o g e t h e r ,i ts h o w e dt h a tr e s i s t i np l a y sa n
important role in the regulation of glucose homeostasis
(e.g. gluconeogenesis) and insulin sensitivity.
Adiponectin-resistin interaction
The interaction effect of adiponectin and resistin was
more strongly associated (P≤2.32x10
-34)w i t hi n c r e a s e d
risk of type 2 diabetes (T2DM) and metabolic syndrome
(MS) compared to hypoadiponectinemia (P = 7.65 × 10
-9)
Figure 1 Association of fasting serum adiponectin levels with T2DM and MS susceptibility (n = 809). Data are expressed as mean (95%
confident interval). ANCOVA test was used, followed by pairwise comparison using 1,000 stratified bootstrap samples with bias corrected and
accelerated (BCa) 95% CI for multiple testing bias corrections due to deviation of normality. The p-value was also adjusted for covariate ages
with stratified ethnicity. The location of statistically significant differences are displayed as the double arrow. Significant levels: P* < 0.05, P** <
0.01, P*** < 0.001. Note: T2DM = type 2 diabetes; MS = metabolic syndrome.
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-29) alone (Table 5,
Figure 1 and Figure 2). The condition of hypoadiponectine-
mia and hyperresistinemia tend to concurrent in subjects
presenting with both T2DM and MS (Figure 1 and Figure
2). Also, serum adiponectin levels were negatively corre-
lated (P = 0.0027) with serum resistin levels (Table 3).
Given the opposite effects of adiponectin and resistin on
the insulin sensitivity, it speculates that relative proportion
of adiponectin-to-resistin might potentially influence the
risk of T2DM and MS (Table 3 and Table 4). Taking these
findings together, it may be speculated that adiponectin
and resistin interact to modulate metabolic homeostasis.
Formulation of the adiponectin-resistin (AR) index
Taking the findings together, it may be speculated that
the integration of adiponectin and resistin in a novel
unified index would be better reflected metabolic home-
ostasis and metabolic disorders. Adiponectin (A0)a n d
resistin (R0) levels having diametrically opposed physio-
logical effects in the present study (Table 3, Table 4,
F i g u r e1a n dF i g u r e2 ) .T h u s ,A 0 and R0 are unified by
multiplicative inverse as follows
 = () ×= 1A R R A // 00 0 0 (1)
Then (1) is logarithmically transformed for normalization,
 ==
=−
log log R A
log R log A
10 10 0 0
10 0 10 0
() ( / )
() ()
(2)
Lastly, a numerical constant 1 is added to (2) to get a
positive integer of the AR index
Table 3 Correlation of the anthropometric clinical and metabolic parameters
Variables Adiponectin
(μg/mL)
(n = 809)
Resistin
(ng/mL)
(n = 809)
AR Index
(n = 809)
Ages (years) r = +0.1347 r = +0.0422 r = -0.0380
P = 1.22 × 10
-4*** P = 0.2299 P = 0.2794
BMI (kg/m
2) r = -0.1480 r = + 0.1266 r = + 0.1753
P = 2.38 × 10
-5 *** P = 3.08 × 10
-4 *** P = 5.27 × 10
-7 ***
Waist (cm) r = -0.2126 r = +0.2104 r = +0.2694
P = 1.01 × 10
-9 *** P = 1.50 × 10
-9 *** P = 6.35 × 10
-15***
WHR r = -0.1765 r = + 0.1911 r = + 0.2370
P = 4.39 × 10
-7 *** P = 4.33 × 10
-8 *** P = 8.67 × 10
-12 ***
Systolic BP (mmHg) r = + 0.0323 r = + 0.0564 r = + 0.0170
P = 0.3586 P = 0.1088 P = 0.6285
Diastolic BP (mmHg) r = + 0.0355 r = -0.0398 r = -0.0591
P = 0.3131 P = 0.2587 P = 0.0931
Total cholesterol (mmol/L) r = +0.0696 r = -0.0648 r = -0.0947
P = 0.0478 * P = 0.0654 P = 0.0070 **
HDL cholesterol (mmol/L) r = +0.3341 r = -0.1065 r = -0.2658
P = 1.53 × 10
-22 *** P = 0.0024 ** P = 1.50 × 10
-14 ***
LDL cholesterol (mmol/L) r = +0.0618 r = -0.0610 r = -0.0849
P = 0.0791 P = 0.0829 P = 0.0157 *
Triglyceride (mmol/L) r = -0.2072 r = +0.0358 r = +0.1349
P = 2.70 × 10
-9 *** P = 0.3093 P = 1.18 × 10
-4 ***
Glucose (mmol/L) r = -0.1725 r = +0.3077 r = +0.3279
P = 8.00 × 10
-7 *** P = 3.36 × 10
-19 *** P = 9.81 × 10
-22 ***
HbA1C (%) r = -0.2254 r = + 0.3291 r = + 0.3716
P = 8.97 × 10
-11 *** P = 6.84 × 10
-22 *** P = 6.82 × 10
-28 ***
Insulin (μU/mL) r = -0.2374 r = + 0.1598 r = + 0.2395
P = 8.00 × 10
-12 *** P = 4.94 × 10
-6 ** P = 5.11 × 10
-12 ***
Adiponectin (μg/mL) NA r = -0.1053 NA
NA P = 0.0027 ** NA
Resistin (ng/mL) r = -0.1053 NA NA
P = 0.0027 ** NA NA
Spearman’s rho rank correlation test was used because most of the variables are not normally distributed. Significant levels: P* < 0.05, P** < 0.01, P*** < 0.001.
Note: r = Spearman’s rho rank correlation coefficient; BMI = body mass index; WHR = waist-to-hip ratio; BP = blood pressure; AR = adiponectin-resistin; NA = not
applicable.
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log R log A
=+
=+ −
1
1 10 0 10 0

() ()
(3a)
Note: R0 = fasting serum total resistin levels in ng/mL;
A0 = fasting serum total adiponectin levels in μg/mL.
Evaluation of the adiponectin-resistin (AR) index
The adiponectin-resistin (AR) index was more strongly
associated (df = 3; F = 70.494; P = 1.77 × 10
-40)w i t h
increased risk of type 2 diabetes (T2DM) and metabolic
syndrome (MS) than adiponectin (df = 3; F = 13.900;
P=7 . 6 5×1 0
-9) and resistin (df = 3; F = 49.165; P =
3.52 × 10
-29) levels alone (Figure 1, Figure 2 and Figure
3). The AR index was the lowest in controls, followed
by the subjects with MS and T2DM (Figure 3). The AR
index was the highest in subjects presenting with both
T2DM and MS (Figure 3).
The normal reference range of the AR index for healthy
individuals was between 1.120 and 1.206 (Figure 3). The
minimum cut-off values of the novel AR index for diag-
nosis of T2DM and MS in Malaysian men were between
1.206 and 1.244 (Figure 3). An individual whose AR
index is 1.244 or greater (indicator for developing MS) is
defined as being in a metabolic syndrome or pre-diabetic
state (Figure 3). When the AR index is 1.379 or greater
(indicator for developing T2DM), the individual is diag-
nosed as having type 2 diabetes (Figure 3). When the AR
index is 1.559 or greater (indicator for developing of
diabetic complications), the individual is diagnosed as
having both type 2 diabetes and metabolic syndrome
(Figure 3). These predictive values of the AR index were
only applicable to Malaysian men with 95% confident
interval (Figure 3).
The AR index was correlated with a higher number of
MS components than adiponectin and resistin levels
alone (Table 3). The AR index was also more strongly
correlated with the insulin resistance indexes and other
risk factors including serum insulin, plasma glucose and
whole blood HbA1C levels than adiponectin and resistin
levels alone (Table 3 and Table 4). Thus, the AR index
may play a greater role in reflecting circulating metabo-
lite levels and insulin sensitivity than adiponectin and
resistin levels alone.
Formulation of the insulin resistance (IRAR) index
Among the existing insulin resistance indexes, quantita-
tive insulin sensitivity check index (QUICKI) had the
stongest correlation (P = 3.71 × 10
-25) with the adipo-
nectin-resistin (AR) index (Table 4). The QUICKI and
AR indexes are formulated as follows
AR index 1 log R log A 11 =+ () − () 00 00 (3b)
QUICKI 1 log I  + log G 11 = () ( ) ⎡ ⎣ ⎤ ⎦ / 00 0 0 (4)
The QUICKI was negatively correlated with the AR
index (Table 4). Therefore, (3) and (4) are unified by
multiplicative inverse as follows
IR  index  AR index QUICKI
1Q U I C K I A R  i n d e x
log
AR
1
= () ( )
= () ×()
=
/
/
0 00 0 0 0 0 0 0
00 0
I log G 1 log R log A
log I G
11 1
1
() + () ⎡ ⎣ ⎤ ⎦ ×+ () − () ⎡ ⎣ ⎤ ⎦
= ()    1l o g R A 1 + () ⎡ ⎣ ⎤ ⎦ 00 0 /
(5)
Lastly, (5) is simplify to become a finalized IRAR index
as follows
IR  index log I G log I G log R A AR 1 1 1 = () + ()( ) 00 0 00 0 0 0 0 / (6)
Note: I0 = fasting serum insulin levels in μU/mL;
G0 = fasting plasma glucose levels in mg/dL;
R0 = fasting serum total resistin levels in ng/mL;
Table 4 Correlation of the insulin resistance indexes
Insulin
resistance
indexes
Adiponectin
(μg/mL)
(n = 809)
Resistin
(ng/mL)
(n = 809)
AR index
(n = 809)
HOMA-IR index r = -0.2639 r = +0.2615 r = +0.3355
P = 2.37 × 10
-14 *** P = 4.04 × 10
-14 *** P = 9.73 × 10
-23 ***
QUICKI r = +0.2736 r = -0.2844 r = -0.3530
P = 1.41 × 10
-16 *** P = 1.63 × 10
-16 *** P = 3.71 × 10
-25 ***
Bennett index r = +0.2690 r = -0.2704 r = -0.3463
P = 7.36 × 10
-15 *** P = 5.27 × 10
-15 *** P = 3.57 × 10
-24 ***
McAuley (1) index r = +0.2824 r = -0.1253 r = -0.2408
P = 2.67 × 10
-16 *** P = 3.54 × 10
-4 *** P = 3.92 × 10
-12 ***
McAuley (2) index r = +0.2799 r = -0.1355 r = -0.2481
P = 5.03 × 10
-16 *** P = 1.11 × 10
-4 *** P = 8.14 × 10
-13 ***
Spearman’s rho rank correlation test was used. Significant levels: P* < 0.05, P** < 0.01, P*** < 0.001. Note: r = Spearman’s rho rank correlation coefficient; HOMA-
IR = homeostasis model assessment of insulin resistance; QUICKI = quantitative insulin sensitivity check index; AR = adiponectin-resistin.
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Evaluation of the insulin resistance (IRAR) index
The insulin resistance (IRAR) index (df = 3; F = 117.190;
P = 5.84 × 10
-63) may better predict insulin resistance
than classical surrogate indexes including the QUICKI
(df = 3; F = 103.892; P = 7.62 × 10
-57)( T a b l e6 ) .T h e
IRAR index was higher in the MS subjects who do not
yet manifest T2DM as compared to the healthy subjects
(Figure 4). The IRAR index was also higher in the T2DM
subjects who do not yet manifest MS as compared to
the healthy subjects (Figure 4). The IRAR index was the
highest in subjects presenting with both T2DM and MS
(Figure 4). In addition, the IRAR index had high

Figure 2 Association of fasting serum resistin levels with T2DM and MS susceptibility (n = 809). Data are expressed as mean (95%
confident interval). ANCOVA test was used, followed by pairwise comparison using 1,000 stratified bootstrap samples with bias corrected and
accelerated (BCa) 95% CI for multiple testing bias corrections due to deviation of normality. The p-value was also adjusted for covariate ages
with stratified ethnicity. The location of statistically significant differences are displayed as the double arrow. Significant levels: P* < 0.05, P** <
0.01, P*** < 0.001. Note: T2DM = type 2 diabetes; MS = metabolic syndrome.
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ment of the insulin resistance (Figure 4).
The normal reference range of the IRAR index for insu-
lin sensitive individuals was between 3.265 and 3.538
(Figure 4). The minimum cut-off values of the novel IRAR
index for insulin resistance assessment in Malaysian men
were between 3.538 and 3.955 (Figure 4). An individual
whose IRAR index is between 3.955 and 4.305 (indicator
for developing MS) is defined as being in a mild insulin
resistance state (Figure 4). An individual whose IRAR
index is between 4.403 and 4.791 (indicator for develop-
ing T2DM) is defined as being in a moderate insulin
resistance state (Figure 4). An individual whose IRAR
index is between 5.305 and 5.612 (indicator for develop-
ing diabetic complications) is defined as being in a severe
insulin resistance state (Figure 4). These predictive values
of the IRAR index were only applicable to Malaysian men
with 95% confident interval (Figure 4).
Discussion
Hypoadiponectinemia
Circulating levels of adiponectin are highly heritable, with
more than 30-70% of its variability explained by genetics
factors [17,18]. A recent comprehensive linkage disequili-
brium mapping revealed many SNPs in the adiponectin
gene (ADIPOQ) were strongly associated with circulating
adiponectin levels [18]. In addition, an extensive bioinfor-
matics analysis revealed the ADIPOQ region might be a
high copy number variable region which potentially influ-
ences circulating adiponectin levels [18]. Furthermore,
ADIPOQ is a major gene influencing circulating adipo-
nectin levels from the genome-wide perspective [18,19].
T h ea r e ao fc h r o m o s o m e3 q 2 7w h e r et h eADIPOQ gene
is located has been identified by genome-wide linkage
studies (GWLSs) to be a susceptibility locus for risk for
the type 2 diabetes (T2DM) [20], metabolic syndrome
(MS) [21] and cardiovascular disease [22,23]. However,
this was not shown in recently published meta-analyses
of genome-wide association studies (GWASs) [24-27].
The ADIPOQ gene is located nearby the IGF2BP2 (insu-
lin-like growth factor 2 mRNA-binding protein 2) and
AOMS1 (abdominal obesity-metabolic syndrome QTL 1)
genes on chromosome 3q27 (based on Ensembl data-
base). The other T2DM and MS susceptibility genes
including HDLCQ5 (high density lipoprotein cholesterol
level QTL 5) (on chromosome 3q24-q26), AGTR1 (angio-
tension receptor 1) (on chromosome 3q24), FGQTL6
(fasting plasma glucose level QTL 6) (on chromosome
3q21), RETNLB (resistin-like beta) (on chromosome
3q13.13), HYT7 (hypertension, essential, susceptibility to,
7) (on chromosome 3p14.1-q12.3), PPARG (peroxisome
proliferator activated receptor gamma) (on chromosome
3p25.2) and ABHD5 (abhydrolase domain containing 5)
(on chromosome 3p25.3-p24.3) may also in linkage dise-
quilibrium with the ADIPOQ gene (based on Ensembl
database). Thus, these genes may influence the functional
mechanism and expression of the ADIPOQ gene includ-
ing adiponectin levels.
Adiponectin has already been identified as a potential
target for therapeutics to treat T2DM [28] and MS [29-31]
in a series of clinical trials. Many existing drugs have been
found to increase adiponectin levels, including statins (e.g.
pravastatin, simvastatin, rosuvastatin and atorvastatin),
angiotensin converting enzyme inhibitors and angiotensin
receptor blockers (e.g. ramipril, quinapril, telmisartan,
irbesartan and candesartan), b-adrenergic agonists, and
thiazolidinediones (e.g. pioglitazone and rosiglitazone)
[32]. Other drugs that increase serum adiponectin levels
were including non-statin anti-hyperlipidemic drugs (e.g.
fenofibrate), non-TZD anti-diabetic drugs (e.g. acarbose
and sulfonylurea glimepiride) and androgen blockers [32].
A meta-analysis including 19 prospective studies had
pointed out an increase in serum adiponectin levels in
subjects undergoing treatment with thiazolidinediones
(TZD) [33]. Moreover, a systematic review including
33 clinical trials showed that exercise of varying prescrip-
tion was able to increase serum adiponectin levels [34].
However, a recent survey revealed the paradoxical findings
regarding the role of adiponectin in human disease [35].
According to the concept of the reversal epidemiology in
the adiponectin physiology, adiponectin would behave as
an insulin sensitizing and cardioprotective factor in the
health state and as a wasting marker in the advanced states
of disease [35].
Hyperresistinemia
Genetic variants in RETN (the resistin gene) have been
examined by many groups, and it was estimated that up
to 70% of the variation in circulating resistin levels
Table 5 Multivariate analysis for adiponecin-resistin
interaction
Multivariate
test
Value F Hypothesis
df
Error
df
P-value
Pillai’s
trace
0.201 29.920 6 1608 3.70 × 10
-34***
Wilks’
lambda
0.803 31.050 6 1606 1.90 × 10
-35***
Hotelling’s
trace
0.241 32.182 6 1604 9.76 × 10
-37***
Roy’s largest
root
0.219 58.779 3 804 2.32 × 10
-34***
MANCOVA test with 1,000 stratified bootstrap samples, and bias corrected
and accelerated (BCa) 95% CI was used for multiple testing bias corrections
due to deviation of normality. The p-value was also adjusted for covariate
ages with stratified ethnicity. The model included adiponectin and resistin
levels as dependent variables, subjects as fixed factors, ages and ethnicity as
covariates. Subjects were comprising of 208 controls, 171 T2DM without MS,
174 MS without T2DM, and 256 T2DM with MS. Significant levels: P* < 0.05,
P** < 0.01, P*** < 0.001. Note: T2DM = type 2 diabetes; MS = metabolic
syndrome.
Lau and Muniandy Cardiovascular Diabetology 2011, 10:8
http://www.cardiab.com/content/10/1/8
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recent fine-mapping of SNP studies which covering the
full RETN gene revealed several SNPs of the RETN gene
account for the high variablity of resistin levels [37]. In
the San Antonio Family Heart Study, the maximum
linkage signal for the RETN expression was found on
chromosome 19p13 (location of the RETN gene) [38]. In
addition, the RETN gene is located nearby the INSR
(insulin receptor) and LDLR (low density lipoprotein
receptor) genes on chromosome 19p13.2 (based on
Ensembl database). This suggests that RETN expression
may be cis-regulated, meaning there are variants in or
near the RETN gene that influence the abundance of its
mRNA [38]. The other T2DM and MS susceptibility

Figure 3 Association of the adiponectin-resistin (AR) index with T2DM and MS susceptibility (n = 809). Data are expressed as mean (95%
confident interval). ANCOVA test was used, followed by pairwise comparison using 1,000 stratified bootstrap samples with bias corrected and
accelerated (BCa) 95% CI for multiple testing bias corrections due to deviation of normality. The p-value was also adjusted for covariate ages
with stratified ethnicity. The location of statistically significant differences are displayed as the double arrow. Significant levels: P* < 0.05, P** <
0.01, P*** < 0.001. Note: T2DM = type 2 diabetes; MS = metabolic syndrome.
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lipoprotein associated) (on chromosome 19p13.3-p13.2),
AKT2 (murine thymoma viral homolog-2) (on chromo-
some 19q13.2), FFAR 1 (free fatty acids receptor 1) (on
chromosome 19q13.12), FFAR 2 (on chromosome
19q13.12) and FFAR 3 (on chromosome 19q13.12) may
also in linkage disequilibrium with the RETN gene (based
on Ensembl database). In the meta-analyses of genome-
wide linkage studies (GWLSs),s u g g e s t i v ee v i d e n c eo f
linkage was observed for LDL cholesterol [39,40], apoli-
poprotein B [39], total cholesterol [40], and HDL choles-
terol [40] on chromosome 19p13. These provide
compelling evidence that the region of chromosome
19p13 harbor important determinants of lipid levels in
individuals with T2DM [40]. However, the RETN gene
was not detected as a susceptibility locus for risk for the
T2DM, MS and cardiovascular disease in recently pub-
lished meta-analyses of genome-wide association studies
(GWASs) [24-27]. Thus, whether the RETN gene modu-
lates metabolic homeostasis independently or functions
in concert with other causative genes in a haplotype
block remains to be elucidated.
Compared to adiponectin, the effects of drugs treatment
on resistin levels in patients with T2DM and MS is less
described. However, a few clinical trials showed that
the anti-diabetic (e.g. rosiglitazone) [41], anti-hypertensive
(e.g. amlodipine) [31] and anti-dyslipidemic (e.g. pitavasta-
tin) [42] drugs were able to reduce circulating resistin
levels and may contribute to improving insulin action in
patients with T2DM and MS. Recently, Koh et al. reported
that amlodipine (a calcium channel blocker) therapies
significantly decreased resistin levels greater than ramipril
(an angiotensin-converting enzyme inhibitor) or candesar-
tan (an angiotensin II receptor antagonist) therapies in
patients with hypertension [31]. In addition, resistin con-
centration decreased after long-term exercise training in
overweight adolescents [43]. A recent long-term follow-up
study revealed elevated serum resistin levels were asso-
ciated with higher rates of mortality and hospitalization for
heart failure [11]. However, serum resistin levels do not
add prognostic information among high-risk persons with
established coronary heart disease [11].
Adiponectin-resistin interaction
In consistent with our study, a significant inverse cor-
relation between serum adiponectin and resistin levels
has also been reported in the literatures [12,13]. It has
been reported that those with highest increases of adi-
ponectin also displayed a trend towards a decline in
resistin levels [13]. Tuttolomondo et al. demonstrated
that diabetic subjects with diabetic foot had higher
resistin levels and lower adiponectin levels compared
to diabetics without diabetic foot [44]. Both hypoadi-
ponectinemia and hyperresistinemia were also posi-
tively correlated with diabetes duration, hypertension,
dyslipidemia, retinopathy, previous cerebrovascular dis-
ease (TIA/ischemic stroke), neuropathy, and diabetic
foot grade [44]. Furthermore, both hypoadiponectine-
mia and hyperresistinemia were associated with out-of-
clinic hypertension [45] and may have prognostic sig-
nificance for future cardiovascular events in patients
with masked hypertension [46]. Elevated resistin
Table 6 Evaluation of insulin sensitivity with the insulin resistance indexes
Subjects
Insulin
resistance
indexes
Control
(n = 208)
group A
MS
without T2DM
(n = 174)
group B
T2DM
without MS
(n = 171)
group C
T2DM
with MS
(n = 256)
group D
F-test; P-value
(A vs. B vs. C vs. D)
HOMA-IR index 2.546 (2.317, 2.779) ) 5.038 (4.334, 5.923) 5.066 (4.367, 5.968) 8.706 (7.476, 10.183) 26.447; 2.55 × 10
-16
B***, C***, D*** A***, D*** A***, D*** A***, B***, C***
QUICKI 0.346 (0.342, 0.351) 0.317 (0.313, 0.320) 0.319 (0.314, 0.324) 0.296 (0.293, 0.299) 103.892; 7.62 × 10
-57
B***, C***, D*** A***, D*** A***, D*** A***, B***, C***
Bennett index 0.309 (0.293, 0.327) 0.228 (0.220, 0.237) 0.240 (0.224, 0.257) 0.181 (0.175, 0.186) 76.614; 1.38 × 10
-43
B***, C***, D*** A***, D*** A***, D*** A***, B***, C***
McAuley (1) index 7.235 (7.009, 7.474) 5.305 (5.151, 5.475) 7.095 (6.845, 7.375) 5.347 (5.187, 5.518) 105.878; 9.02 × 10
-58
B***, D*** A***, C*** B***, D*** A***, C***
McAuley (2) index 7.447 (7.227, 7.664) 5.496 (5.326, 5.651) 7.331 (7.103, 7.580) 5.486 (5.336, 5.627) 120.944; 1.20 × 10
-64
B***, D*** A***, C*** B***, D*** A***, C***
IRAR index 3.401 (3.265, 3.538) 4.132 (3.955, 4.305) 4.604 (4.403, 4.791) 5.455 (5.305, 5.612) 117.190; 5.84 × 10
-63
B***, C***, D*** A***, C**, D*** A***, B**, D*** A***, B***, C***
Data are expressed as mean (95% confident interval). ANCOVA test was used, followed by pairwise comparison using 1,000 stratified bootstrap samples with bias
corrected and accelerated (BCa) 95% CI for multiple testing bias corrections due to deviation of normality. The p-value was also adjusted for covariate ages with
stratified ethnicity. The location of statistically significant differences are displayed as group’s name (A, B, C, or D). Significant levels: P* < 0.05, P** < 0.01, P*** <
0.001. Note: T2DM = type 2 diabetes; MS = metabolic syndrome; HOMA-IR = homeostasis model assessment of insulin resistance; QUICKI = quantitative insulin
sensitivity check index, IRAR = insulin resistance (adiponectin-resistin).
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b eas t r o n gp r e d i c t i v ef a c t o rf o rt h eo c c u r r e n c eo f
major adverse cardiac events in patients with stable
multivessel coronary artery disease over 1-year follow-
up [47]. A recent prospective longitudinal pilot trial
revealed systemic therapy ameliorates endothelial cell
function by increase adiponectin and decrease resistin
levels in patients with plaque-type psoriasis [48].
In addition, analysis with (18)F-fluorodeoxyglucose
positron emission tomography revealed both adiponec-
tin and resistin may be useful as biomarkers to reflect
vascular inflammation [49]. Thus, the balance of the
opposite effects of adiponectin and resistin at the level
of the endothelial cell may be an important
Figure 4 Evaluation of insulin sensitivity with the insulin resistance (IRAR) index (n = 809). Data are expressed as mean (95% confident
interval). ANCOVA test was used, followed by pairwise comparison using 1,000 stratified bootstrap samples with bias corrected and accelerated
(BCa) 95% CI for multiple testing bias corrections due to deviation of normality. The p-value was also adjusted for covariate ages with stratified
ethnicity. The location of statistically significant differences are displayed as the double arrow. Significant levels: P* < 0.05, P** < 0.01, P*** <
0.001. Note: T2DM = type 2 diabetes; MS = metabolic syndrome.
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progress of atherosclerosis.
Several studies have illustrated the interaction between
adipokines (including adiponectin and resistin) and ade-
nosine 5’ monophosphate-activated protein kinase
(AMPK), and highlighted AMPK as a potential target
for the development of tissue-specific AMPK modula-
tors in the treatment of T2DM and MS [50]. In patients
with metabolic syndrome, thiazolidinediones (TZDs)
including pioglitazone [51] and rosiglitazone [52] treat-
ment markedly increased adiponectin and decreased
resistin levels. These treatment effects on both adipo-
nectin and resistin may further contribute to the AMPK
activation exerted by TZDs [52]. A recent randomized
double blind clinical trial demonstrated that short-term
treatment with losartan (an angiotensin II receptor
antagonist drug) improved both adiponectin and resistin
levels in hypertensive subjects [53]. Furthermore, fenofi-
brate therapy improved both adiponectin and resistin
levels, and may directly contribute to improving insulin
sensitivity in hypertriglyceridemic patients [54]. These
may in turn exert detrimental and beneficial effects on
glucose and lipid metabolism.
Crosstalk of adipokines including adiponectin and
resistin at the expression level and/or sites of brain’s
central action may eventually lead to the development
and perpetuation of T2DM and MS [55]. The intricate
interactions between adiponectin and resistin with cate-
c h o l a m i n e sm a yp l a ya ni n t e g r a lr o l ei nm e t a b o l i s m
[56]. In addition, adipocyte-derived microvesicles
mediated transport of adiponectin and resistin gene
transcripts into macrophages and might play a role as a
novel intercellular communication tool by transporting
RNA in paracrine and possibly endocrine manners [57].
Miyamoto et al. found that resistin may increase the
susceptibility of metabolic syndrome by modulating adi-
ponectin secretion from adipocytes [58]. Resistin may
enhance hepatic gluconeogenesis, presumably by antago-
nizing adiponectin, which inhibits enzymes involved in
gluconeogenesis through AMPK activation [58]. Further-
more, SNP-420C > G of the resistin gene was associated
with lower circulating adiponectin levels in a Japanese
cohort study [58]. Thus, the transcriptional activity of
the resistin gene may also influence circulating adipo-
nectin levels.
Adiponectin [7] and resistin [10] hormones are con-
sidered significant root factors for the regulation of
energy, glucose, and lipid homeostasis as well as insulin
signalling pathway. Moreover, it has been reported that
the overall structure of multimeric assembly of the resis-
tin is similar to that of adiponectin [14]. Both have been
characterized as coiled-coil trimers that formed tail-to-
tail hexamers through disulfide bonds near their amino
termini [14]. Furthermore, both of these hormones
circulate in serum in two distinct assembly states [14].
The comparable domain architecture of these two adi-
pocyte-specific hormones, despite having diametrically
opposed physiological effects, suggested a common reg-
ulatory mechanism in metabolic homeostasis [14].
The adiponectin-resistin (AR) index
It has been reported that the adiponectin-resistin ratio
might be potentially useful in prediction of the future
cardiovascular risk in women with the polycystic ovary
syndrome [13]. Moreover, changes of the relative pro-
portion of adiponectin to resistin might play a more
important role in hormonal disturbances in polycystic
ovary syndrome than the absolute concentrations of
these adipokines [59]. In addition, mice under chronic
variable stress and fed with a high-fat diet showed
impaired glucose tolerance associated with low plasma
adiponectin-resistin ratios [60]. It seems that changes of
circulating adiponectin and resistin levels may be the
effect of their mutual interaction in adipose tissue.
Thus, the AR index that included information on both
serum adiponectin and resistin levels may has a more
integrated and concentrated explanation than single
measure of serum adiponectin and resistin levels in the
present study.
Taking these studies together, adiponectin and resistin
m a yb eu s e f u lm a r k e r sf o ri n s u l i nr e s i s t a n c ea n dt h e
variables that can integrate the abnormalities of the
metabolic syndrome and cardiometabolic function. For
this reason we attempted to estimate a threshold for the
AR index for the identification of T2DM and MS.
Although further studies may be necessary to confirm
the efficacy of periodically measuring AR index in the
management of insulin resistance, MS and T2DM, our
study certainly highlights the potential for the AR index
to move one step closer to becoming an established bio-
marker of the metabolic status. The evaluation of inter-
vention strategies can be facilitated and strengthened by
the use of the AR index that measure biological para-
meters of disease progression and therapeutic response.
Routine assessment of the AR index may allow for a
better understanding of the underlying disease condi-
tions and optimization of anti-diabetic therapy targeting
beyond simple glycemic control. Thus, the AR index has
a potential for routinely available in general clinical
practice and make a meaningful contribution to patient
care.
The insulin resistance (IRAR) index
Given the complicated nature of the euglycemic hyperin-
sulinemic clamp technique and the potential dangers of
hypoglycemia in some patients, alternatives have been
sought to simplify the measurement of insulin resistance.
In recent years, several markers have been proposed for
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insulin resistance. However, all have problems that limit
their use to research studies. None succeeds in integrat-
ing the global assessment of the metabolic abnormalities
that may increase risk for developing type 2 diabetes
(T2DM) and metabolic syndrome (MS).
Compared to other classical insulin resistance indexes,
quantitative insulin sensitivity check index (QUICKI)
was reported to have the advantage of being applicable
to wider ranges of insulin sensitivity and more reprodu-
cible [61]. It has been showed that QUICKI was among
the most accurate and useful surrogate indexes for
determining insulin sensitivity in humans [62]. However,
QUICKI and insulin action do not correlate highly, par-
ticularly in individuals with mildly insulin resistance,
impaired glucose tolerance or elderly patients with
poorly controlled T2DM [63]. Moreover, QUICKI is less
robust for early diagnosis of insulin resistance in persons
without T2DM or MS [63]. QUICKI has low sensitivity
for detecting insulin resistance in lean individuals with
beta cell dysfunction [63]. QUICKI use fasting glucose
levels in their calculations and fasting glucose levels are
steady-state levels that are not a reflection of glucose
utilization after a glucose load [62]. Also, QUICKI
reflects hepatic insulin resistance only, not insulin resis-
tance at peripheral tissues [63].
The recently developed HOMA-AD was a more accu-
rate indicator for assessing insulin resistance than the
HOMA-IR [64]. HOMA-AD is a modified version of
homeostasis model assessment of insulin resistance
(HOMA-IR) index which calculated from the product of
serum insulin and plasma glucose levels divided by
serum adiponectin levels [64]. Modification of HOMA-
IR with adiponectin levels resulted in an index exhibit-
ing a good correlation with M-values even in diabetic
patients with moderate hyperglycemia [64]. In addition,
Zaletel et al. showed that the adiponectin derived index
correlated best with the euglycemic hyperinsulinemic
clamp derived sensitivity index compared to other sur-
rogate measures of insulin resistance including HOMA-
IR, QUICKI, fasting glucose/insulin ratio or McAuley
index [65]. A recent electron spin resonance study
revealed adiponectin might has a close correlation with
rheological behavior and microcirculation in hyperten-
sion [66]. Moreover, adiponectin may be a marker for
global metabolic status including insulin resistance and
metabolic syndrome [67].
It is well-established that insulin resistance in adipose
tissue will lead to elevated serum resistin levels and
reduced serum adiponectin levels [10]. Lipolysis plays a
role in the developing of insulin resistance in healthy
subjects, with an estimated overall contribution of
approximately 39% [68]. Increased lipolysis in adipose
tissues was associated with elevation of systemic free
fatty acids and insulin resistance [69]. Adiponectin in
physiological concentrations inhibits spontaneous as
well as catecholamine-induced lipolysis [70]. Resistin
induces lipolysis and re-esterification of triacylglycerol
stores, and increases cholesteryl ester deposition, in
human macrophages [71]. Therefore, inclusion of adipo-
nectin and resistin into the QUICKI formula can be
beneficial and can increase its detection power by
including those subjects with peripheral insulin resis-
tance, especially in view of the following: increased fast-
ing resistin levels [71] and reduced fasting adiponectin
levels [70] could reflect insulin resistance earlier than
hyperglycemia since lipolysis was more sensitive to insu-
lin than glucose utilization; a small increase in resistin
[72] and decrease in adiponectin levels [73] in healthy
individuals were reported to induce insulin resistance;
insulin resistance of lipolysis induced by adiponectin
and resistin were suggested as explaining a large varia-
tion in insulin sensitivity of glucose disposal in lean
individuals [69].
It has been well-reported that adiponectin [67] and
resistin [6] are promising biomarkers of insulin resistance.
A recent clinical trial revealed pioglitazone plus vildaglip-
tin treatment improved both adiponectin and resistin
levels and might effective in preserving beta-cell function,
and in reducing insulin resistance and inflammatory state
parameters in subjects with poorly controlled T2DM [74].
Moreover, the imbalance in deleterious and protective adi-
pokines including adiponectin and resistin plays pivotal
roles in the development and progression of pancreatic
beta-cell dysfunction under insulin-resistant conditions
[75]. Adiponectin and resistin levels were also strongly
correlated with the key metabolic endpoints of T2DM and
MS as well as insulin sensitivity in the present study
(Table 3 and Table 4). Therefore, we generated a modified
version of QUICKI, the novel IRAR index by taking
account into adiponectin and resistin levels. The IRAR
index clearly had the narrowest and most favourable dis-
tribution of residuals among the surrogate indexes (Table 6
a n dF i g u r e4 ) .T h eI R AR index may has higher precision,
consistency, reproducibility and robustness than classical
surrogate indexes (Table 6 and Figure 4). Thus, we
hypothesized that the IRAR index may be a more appropri-
ate model of insulin sensitivity than other surrogate
indexes in Malaysian men.
The reported values for the definition of insulin resis-
tance vary widely. A World Health Organization (WHO)
consensus group concluded that the insulin sensitivity
index of the lowest 25% of a general population can be
considered as an insulin resistance state [76]. The Eur-
opean Group for the Study of Insulin Resistance take a
more restricted view, defining insulin resistance as the
insulin sensitivity index of the lowest 10% of a nonobese,
nondiabetic, normotensive white population [77].
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required to validate the suggestive reference range or
minimum cut-off values of insulin sensitivity for the IRAR
index in Malaysian men. In addition, long-term prospec-
tive studies are required to determine the actual refer-
ence range or minimum cut-off values of the novel IRAR
index for insulin resistance assessment in the general
population. The novel IRAR indexes give an opportunity
to implement and use of this index in the daily clinical
practice for screening persons with increased risk of
future development of T2DM and MS due to insulin
resistance. It is also very useful for monitoring the dis-
eases progression and therapeutic response. Furthermore,
it will allow early treatment or delay the onset of long-
term severe complications such as cardiovascular risk.
Strengths and limitations
This represent a first attempt to study the interaction
effect of adiponectin and resistin in the modulation of
the key metabolic endpoints of T2DM and MS. Our
samples comprised of Malay, Chinese and Indian sub-
jects from Malaysia, which represented a major segment
of the Asian population. The covariates in term of ages
and ethnicity were in homogeneity and were matched
with the case-control groups (Table 1). Most potential
confounders were carefully controlled for, which limits
the possibility of residual confounding effect. Given the
well-established difference in circulating adiponectin
[8,67] and resistin [6] levels between men and women,
our samples were only comprised male subjects to avoid
the confounding effect of gender. Clinical measurements
were taken under standardized protocol and biomarkers
were measured using assays with good precision (Addi-
tional file 1, Figure S1 and Additional file 1, Supplemen-
tary Methods). Although it has been reported that
various definitions of MS hold different predictive
powers in detecting pathological levels of key adipocyto-
kines such as hypoadiponectinemia and hyperresistine-
mia, the International Diabetes Federation (IDF)
definition is quantitatively more powerful than its coun-
terparts in terms of prevalence [4,78]. The IDF defini-
tion incorporates ethnicity by providing different criteria
for the MS in different ethnic groups [4]. Moreover, the
IDF definition is the most updated and globally accepted
definition for MS [4].
Nevertheless, this study had limitations. The findings
apply mainly to Malaysian men and may not be widely
generalizable because of the homogeneity of the study
population. Since this is not a prospective study, this
study may have reverse causation due to possible effects
of T2DM and MS on adiponectin and resistin levels.
The results were based on single measurements of the
adipokines and therefore may not reflect long-term
exposure to these hormones. Although adjusted for
known confounding factors, residual confounders imper-
fectly measured or unmeasured cannot be excluded.
We measured total adiponectin and not the high
molecular weight fraction, which has been proposed to
have substantially more potent effects on hepatic insulin
sensitivity compared with total adiponectin [79]. How-
ever, a recent study showed that total and high-molecu-
lar-weight (HMW) adiponectin have similar utility for
the identification of insulin resistance and metabolic dis-
t u r b a n c e s[ 6 7 ] .T h i ss u g g e s t ed that total adiponectin
levels may provide clinical information of the same diag-
nostic value as HMW adiponectin [67]. It has been
reported that the low molecul a rw e i g h tf o r mo fr e s i s t i n
displays significantly increased bioactivity [14]. However,
the high molecular weight hexamer of resistin is predo-
minant in the human circulation [14]. Moreover, the
measurement of total adiponectin and resistin are better
standardized, cheaper and more accessible than the
high-molecular-weight adiponectin and the low-molecu-
lar-weight resistin. Thus, our findings may stimulate the
use of adiponectin and resistin in clinical and epidemio-
logical settings.
T h ee u g l y c e m i ch y p e r i n s u linemic clamp technique
must be used as a gold standard index of insulin resis-
tance to validate the robustness of the IRAR index
before their widespread use. Further studies are
required to investigate whether the superior predictive
power of the AR and IRAR indexes demonstrated in
the present study translates into a significant clinical
benefit. The AR and IRAR indexes are unlikely to be
cost-effective for short-time administration of these
indexes. However, the AR and IRAR indexes are good
indicator for long-term metabolic status. Thus, it will
be very cost-effective for long-time administration
since the frequency of monitoring the disease progres-
sion and therapeutic response periodically will be
greatly reduced. A long-term prospective research is
needed to reveal the predictive value of the AR and
IRAR indexes for insulin resistance in association with
T2DM and MS, and to find their optimal cutoff values
for future risk assessment and disease prevention.
Moreover, the normal AR and IRAR indexes range
need to be established for each laboratory with an
appropriate control group because of significant inter-
laboratory variations in insulin and adipokines (includ-
ing adiponectin and resistin) determinations and/or
possible differences in various populations.
Conclusions
The novel AR and IRAR indexes are cost-effective, pre-
cise, reproducible and reliable integrated diagnostic bio-
markers of insulin sensitivity for screening subjects with
increased risk of future development of T2DM and MS.
These surrogate indexes are useful for early diagnosis of
Lau and Muniandy Cardiovascular Diabetology 2011, 10:8
http://www.cardiab.com/content/10/1/8
Page 15 of 18insulin resistance, T2DM and MS in the daily clinical
practice and for large-scale clinical investigation.
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resistin.
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